Background Psychiatric patients often require chronic treatment with antipsychotic drugs, and while rats are frequently used to study antipsychotic-induced metabolic adverse effects, long-term exposure has only partially mimicked the appetite-stimulating and weight-inducing effects found in the clinical setting. Antipsychotic-induced effects on serum lipids are also inconsistent in rats, but in a recent study we demonstrated that subchronic treatment with the orexigenic antipsychotic olanzapine resulted in weight-independent increase in serum triglycerides and activation of lipogenic gene expression in female rats. In addition, a recent long-term study in male rats showed that chronic treatment with antipsychotic drugs induced dyslipidemic effects, despite the lack of weight gain. Aims In the current study, we sought to examine long-term effects of antipsychotic drugs on weight gain, lipid levels and lipid composition after twice-daily administration of antipsychotics to female rats, and to investigate potential beneficial effects of the lipid-lowering agent tetradecylthioacetic acid (TTA), a modified fatty acid. Methods Female rats were exposed to orexigenic antipsychotics (olanzapine or clozapine), metabolically neutral antipsychotics (aripiprazole or ziprasidone), or TTA for 8 weeks. Separate groups received a combination of clozapine and TTA or olanzapine and TTA. The effects of TTA and the combination of olanzapine and TTA after 2 weeks were also investigated. Results The antipsychotic-induced weight gain and serum triglyceride increase observed in the subchronic setting was not present after 8 weeks of treatment with antipsychotics, while lipid-lowering effect of TTA was much more pronounced in the chronic than in the subchronic setting, with concomitant upregulation of key oxidative enzymes in the liver. Unexpectedly, TTA potentiated weight gain in rats treated with antipsychotics. Conclusion TTA is a promising candidate for prophylactic treatment of antipsychotic-induced dyslipidemic effects, but a more valid long-term rat model for antipsychotic-induced metabolic adverse effects is required.
References
[1]
Buchanan RW, Kreyenbuhl J, Kelly DL, Noel JM, Boggs DL, et al. (2010) The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr Bull 36: 71–93.
[2]
Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, et al. (1999) Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 156: 1686–1696.
[3]
Blouin M, Tremblay A, Jalbert ME, Venables H, Bouchard RH, et al. (2008) Adiposity and eating behaviors in patients under second generation antipsychotics. Obesity (Silver Spring) 16: 1780–1787.
[4]
Cooper GD, Pickavance LC, Wilding JP, Halford JC, Goudie AJ (2005) A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berlin) 181: 80–89.
[5]
Kluge M, Schuld A, Himmerich H, Dalal M, Schacht A, et al. (2007) Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study. J Clin Psychopharm 27: 662–666.
[6]
Leucht S, Corves C, Arbter D, Engel RR, Li C, et al. (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 373: 31–41.
[7]
Pouzet B, Mow T, Kreilgaard M, Velschow S (2003) Chronic treatment with antipsychotics in rats as a model for antipsychotic-induced weight gain in human. Pharmacol Biochem Behav 75: 133–140.
[8]
Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, et al. (2010) Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophrenia Research 123: 225–233.
[9]
Albaugh VL, Vary TC, Ilkayeva O, Wenner BR, Maresca KP, et al. (2012) Atypical antipsychotics rapidly and inappropriately switch peripheral fuel utilization to lipids, impairing metabolic flexibility in rodents. Schizophr Bull 38: 153–166.
[10]
Chintoh AF, Mann SW, Lam L, Giacca A, Fletcher P, et al. (2009) Insulin resistance and secretion in vivo: effects of different antipsychotics in an animal model. Schizophrenia Research 108: 127–133.
[11]
Smith GC, Chaussade C, Vickers M, Jensen J, Shepherd PR (2008) Atypical antipsychotic drugs induce derangements in glucose homeostasis by acutely increasing glucagon secretion and hepatic glucose output in the rat. Diabetologia 51: 2309–2317.
[12]
Jassim G, Skrede S, Vazquez MJ, Wergedal H, Vik-Mo AO, et al. (2012) Acute effects of orexigenic antipsychotic drugs on lipid and carbohydrate metabolism in rat. Psychopharmacology (Berl) 219: 783–794.
[13]
Arjona AA, Zhang SX, Adamson B, Wurtman RJ (2004) An animal model of antipsychotic-induced weight gain. Behav Brain Res 152: 121–127.
[14]
Cooper GD, Pickavance LC, Wilding JP, Halford JC, Goudie AJ (2005) A parametric analysis of olanzapine-induced weight gain in female rats. Psychopharmacology (Berl) 181: 80–89.
[15]
Kalinichev M, Rourke C, Daniels AJ, Grizzle MK, Britt CS, et al. (2005) Characterisation of olanzapine-induced weight gain and effect of aripiprazole vs olanzapine on body weight and prolactin secretion in female rats. Psychopharmacology (Berlin) 182: 220–231.
[16]
Deng C, Lian J, Pai N, Huang XF (2012) Reducing olanzapine-induced weight gain side effect by using betahistine: a study in the rat model. J Psychopharmacol 26: 1271–1279.
Albaugh VL, Henry CR, Bello NT, Hajnal A, Lynch SL, et al. (2006) Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity (Silver Spring) 14: 36–51.
[19]
Baptista T, Mata A, Teneud L, de Quijada M, Han HW, et al. (1993) Effects of long-term administration of clozapine on body weight and food intake in rats. Pharmacol Biochem Behav 45: 51–54.
[20]
Davoodi N, Kalinichev M, Korneev SA, Clifton PG (2009) Hyperphagia and increased meal size are responsible for weight gain in rats treated sub-chronically with olanzapine. Psychopharmacology (Berl) 203: 693–702.
[21]
Fell MJ, Anjum N, Dickinson K, Marshall KM, Peltola LM, et al. (2007) The distinct effects of subchronic antipsychotic drug treatment on macronutrient selection, body weight, adiposity, and metabolism in female rats. Psychopharmacology (Berlin) 194: 221–231.
[22]
McNamara RK, Jandacek R, Rider T, Tso P, Cole-Strauss A, et al. (2011) Atypical antipsychotic medications increase postprandial triglyceride and glucose levels in male rats: relationship with stearoyl-CoA desaturase activity. Schizophr Res 129: 66–73.
[23]
Skrede S, Ferno J, Vazquez MJ, Fjaer S, Pavlin T, et al. (2012) Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int J Neuropsychopharmacol 15: 163–179.
[24]
Procyshyn RM, Wasan KM, Thornton AE, Barr AM, Chen EY, et al. (2007) Changes in serum lipids, independent of weight, are associated with changes in symptoms during long-term clozapine treatment. J Psychiatry Neurosci 32: 331–338.
[25]
Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, et al. (2008) Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharm 28: 132–137.
[26]
Wensaas AJ, Rustan AC, Rokling-Andersen MH, Caesar R, Jensen J, et al. (2009) Dietary supplementation of tetradecylthioacetic acid increases feed intake but reduces body weight gain and adipose depot sizes in rats fed on high-fat diets. Diabetes Obes Metab 11: 1034–1049.
[27]
Asiedu DK, al-Shurbaji A, Rustan AC, Bjorkhem I, Berglund L, et al. (1995) Hepatic fatty acid metabolism as a determinant of plasma and liver triacylglycerol levels. Studies on tetradecylthioacetic and tetradecylthiopropionic acids. Eur J Biochem 227: 715–722.
[28]
Morken T, Bohov P, Skorve J, Ulvik R, Aukrust P, et al. (2011) Anti-inflammatory and hypolipidemic effects of the modified fatty acid tetradecylthioacetic acid in psoriasis–a pilot study. Scand J Clin Lab Invest 71: 269–273.
[29]
Lovas K, Rost TH, Skorve J, Ulvik RJ, Gudbrandsen OA, et al. (2009) Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-alpha/delta activation and increased mitochondrial fatty acid oxidation. Diabetes Obes Metab 11: 304–314.
[30]
Han M, Deng C, Burne TH, Newell KA, Huang XF (2008) Short- and long-term effects of antipsychotic drug treatment on weight gain and H1 receptor expression. Psychoneuroendocrinology 33: 569–580.
[31]
Rozen S, Skaletsky H (2000) Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol 132: 365–386.
[32]
Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc 3: 1101–1108.
[33]
Berge RK, Flatmark T, Osmundsen H (1984) Enhancement of long-chain acyl-CoA hydrolase activity in peroxisomes and mitochondria of rat liver by peroxisomal proliferators. Eur J Biochem 141: 637–644.
[34]
Bremer J (1981) The effect of fasting on the activity of liver carnitine palmitoyltransferase and its inhibition by malonyl-CoA. Biochim Biophys Acta 665: 628–631.
[35]
Madsen L, Froyland L, Dyroy E, Helland K, Berge RK (1998) Docosahexaenoic and eicosapentaenoic acids are differently metabolized in rat liver during mitochondria and peroxisome proliferation. J Lipid Res 39: 583–593.
[36]
Skorve J, al-Shurbaji A, Asiedu D, Bjorkhem I, Berglund L, et al. (1993) On the mechanism of the hypolipidemic effect of sulfur-substituted hexadecanedioic acid (3-thiadicarboxylic acid) in normolipidemic rats. J Lipid Res 34: 1177–1185.
[37]
Small GM, Burdett K, Connock MJ (1985) A sensitive spectrophotometric assay for peroxisomal acyl-CoA oxidase. Biochem J 227: 205–210.
[38]
Horton JD, Goldstein JL, Brown MS (2002) SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109: 1125–1131.
[39]
Ferno J, Raeder MB, Vik-Mo AO, Skrede S, Glambek M, et al. (2005) Antipsychotic drugs activate SREBP-regulated expression of lipid biosynthetic genes in cultured human glioma cells: a novel mechanism of action? Pharmacogenomics J 5: 298–304.
[40]
Ferno J, Skrede S, Vik-Mo AO, Havik B, Steen VM (2006) Drug-induced activation of SREBP-controlled lipogenic gene expression in CNS-related cell lines: marked differences between various antipsychotic drugs. BMC Neurosci 7: 69.
[41]
Raeder MB, Ferno J, Vik-Mo AO, Steen VM (2006) SREBP activation by antipsychotic- and antidepressant-drugs in cultured human liver cells: relevance for metabolic side-effects? Mol Cell Biochem 289: 167–173.
[42]
Minet-Ringuet J, Even PC, Valet P, Carpene C, Visentin V, et al. (2007) Alterations of lipid metabolism and gene expression in rat adipocytes during chronic olanzapine treatment. Molecular Psychiatry 12: 562–571.
[43]
Goudie AJ, Smith JA, Halford JC (2002) Characterization of olanzapine-induced weight gain in rats. Journal of Psychopharmacology 16: 291–296.
[44]
Virtue S, Vidal-Puig A (2010) Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome–an allostatic perspective. Biochimica et Biophysics Acta 1801: 338–349.
[45]
McNamara RK, Magrisso IJ, Hofacer R, Jandacek R, Rider T, et al. (2012) Omega-3 fatty acid deficiency augments risperidone-induced hepatic steatosis in rats: positive association with stearoyl-CoA desaturase. Pharmacol Res 66: 283–291.
[46]
Gudbrandsen OA, Wergedahl H, Bohov P, Berge RK (2009) The absorption, distribution and biological effects of a modified fatty acid in its free form and as an ethyl ester in rats. Chem Biol Interact 179: 227–232.
[47]
Attie AD, Krauss RM, Gray-Keller MP, Brownlie A, Miyazaki M, et al. (2002) Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia. J Lipid Res 43: 1899–1907.
[48]
Miyazaki M, Kim YC, Ntambi JM (2001) A lipogenic diet in mice with a disruption of the stearoyl-CoA desaturase 1 gene reveals a stringent requirement of endogenous monounsaturated fatty acids for triglyceride synthesis. J Lipid Res 42: 1018–1024.
[49]
Mandard S, Muller M, Kersten S (2004) Peroxisome proliferator-activated receptor alpha target genes. Cell Mol Life Sci 61: 393–416.
[50]
Virtue S, Vidal-Puig A (2010) Adipose tissue expandability, lipotoxicity and the Metabolic Syndrome–an allostatic perspective. Biochim Biophys Acta 1801: 338–349.
[51]
Kim JY, van de Wall E, Laplante M, Azzara A, Trujillo ME, et al. (2007) Obesity-associated improvements in metabolic profile through expansion of adipose tissue. J Clin Invest 117: 2621–2637.
[52]
Stefanidis A, Verty AN, Allen AM, Owens NC, Cowley MA, et al. (2009) The role of thermogenesis in antipsychotic drug-induced weight gain. Obesity (Silver Spring) 17: 16–24.
[53]
Urichuk L, Prior TI, Dursun S, Baker G (2008) Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr Drug Metab 9: 410–418.
[54]
Berge RK, Hvattum E (1994) Impact of cytochrome P450 system on lipoprotein metabolism. Effect of abnormal fatty acids (3-thia fatty acids). Pharmacol Ther 61: 345–383.
